References
- BoseIli E, Allaouchiche B. Diffusion osseuse des antibio-tiques. Presse Med 1999; 28: 2265–2276.
- Tod M, Padoin C, Petitjean O. Clinical pharmacokinet-ics and pharmacodynamics of isepamicin. Clin Pharmacokinet 2000; 38: 205–223.
- Barr WH, Colucci R, Radwanski E, et al. Pharmacokinetics of isepamicin. J Chemother 1995; 7 (Suppl. 2): 53-61.
- Lin CC, Radwanski E, Korduba C, Cayen N, Affrime M. Pharmacokinetics of intravenous administed isepamicin in men. Antimicrob Agents Chemother 1995; 39: 2774–2778.
- Radwanski E, Batra V, Cayen N, et al. Pharmacokinetics of isepamicin following a single administra-tion by intravenous infusion or intramuscular injections. Antimicrob Agents Chemother 1997; 41: 1794–1796.
- Uematsu T, Mizuno A, Suzuki Y, Sato R, Yamazaki T, Nakashima M. Evaluation of fluorescence polarization immunoassay procedure for quantification of isepamicin, a new aminoglycoside antibiotic. Ther Drug Monit 1988; 10: 459–462.
- Ellner PD, Neu HC. The inhibitory quotient - A method for interpreting minimum inhibitory concentration data. JAMA 1981; 246: 1575–1578.
- Petitjean O, Jehl F, Tod M. Pênêtration tissulaire des antibiotiques. In Infections et antibiothêrapie en reanimation, aux urgences et en chirurgie. (Martin C, Gouin F, Eds), Rueil-Malmaison: Arnette. 2001: 1029-1103.
- Souza E, Munoz P. Micro-organisms responsible for osteoarticular infections. Bailliere's Best Pract Res Clin Rheumatol 1999; 13: 21–35.
- Jones RN. Isepamicin (SCH 21420, 1-N-HAPA Gentamicin B): Microbiological characteristics including antimi-crobial potency and spectrum of activity. J Chemother 1995; 7 (Suppl. 2): 7-16.
- Carbon C. Overview of the efficacy of isepamicin in the adult core clinical trial programme. J Chemother 1995; 7 (Suppl. 2): 79-86.
- Breilh D, Allaouchiche B, Jaumain H, et al. Pharmacokinetics of isepamicin during continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 1999; 43: 2409–2411.